CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
Cardinal Health beat fiscal Q4 earnings-per-share estimates on strong pharmaceutical segment performance, though revenues fell short of expectations. The company also issued fiscal 2027 guidance indicating continued earnings growth.
Why it matters — A CAH watcher would care because the earnings beat and positive forward guidance signal underlying strength in Cardinal Health's core pharma business despite the revenue miss.